In Cystic Fibrosis (CF), the airways are often colonized by opportunistic fungi. The most frequently detected mold is Aspergillus fumigatus (Af). Af diseases are associated with significant morbidity and mortality. The most common clinical picture caused by Af is allergic bronchopulmonary aspergillosis (ABPA), triggered by an immunological reaction against Af. Af bronchitis and invasive aspergillosis rarely occur in CF as a result of spore colonization and germination. Since pulmonary mycoses and exacerbations by other pathogens overlap in clinical, radiological, and immunological characteristics, diagnosis still remains a challenge. The search for reliable, widely available biomarkers for Af diseases is therefore still an important task today.

Af-specific IgG m3 is broadly available. Sensitivity and specificity data are contradictory and differ depending on the study population. In our prospective study on pulmonary Af diseases in CF, we determined specific IgG m3 in order to test its suitability as a biomarker for acute Af diseases and as a follow-up parameter.

In this prospective single center study, 109 patients with CF were screened from 2016 to 2019 for Af-associated diseases. According to diagnostic criteria, they were divided into four groups (control, bronchitis, ABPA, pneumonia). The groups were compared with respect to the level of Af-specific IgG (ImmunoCAP Gm3). We performed a receiver operating characteristic (ROC) curve analysis to determine cut-off, sensitivity and specificity. Twenty-one patients could be enrolled for a follow-up examination.

Of the 109 patients, 36 were classified as acute Af-disease (Af bronchitis, ABPA, Af pneumonia). Of these, 21 patients completed follow up-screening. The median Af-specific Gm3 was higher in the acute Af-disease groups. There was a significant difference in Af-specific IgG m3 compared to the control group without acute Af-disease. Overall, there was a large interindividual distribution of Gm3. A cut-off value of 78.05 mg/L for Gm3 was calculated to discriminate controls and patients with ABPA/pneumonia with a specificity of 75% and a sensitivity of 74.6%. The follow up examination of 21 patients showed a decrease of Gm3 in most patients without statistical significance due to the small number of follow up patients.

Af specific IgG may be a useful biomarker for acute ABPA and Af pneumonia, but not for Af bronchitis in CF. However, due to the large interindividual variability of Gm3, it should only be interpreted alongside other biomarkers. Therefore, due to its broad availability, it could be suitable as a biomarker for ABPA and Af pneumonia in CF, if the results can be supported by a larger multicenter cohort.

在囊性纤维化（CF）中，气道通常被机会性真菌定植。最常检测到的霉菌是烟曲霉 （f）。 f疾病与明显的发病率和死亡率有关。最常见的临床原因是f 是过敏性支气管肺曲霉病（ABPA），由针对 f。 f由于孢子定殖和发芽，支气管炎和侵袭性曲霉病很少在CF中发生。由于其他病原体的肺真菌病和加重在临床，放射学和免疫学特征上重叠，因此诊断仍然是一个挑战。寻找可靠的，广泛使用的生物标志物f 因此，疾病仍然是当今的重要任务。

f特异性IgG m3广泛可用。敏感性和特异性数据是矛盾的，并且取决于研究人群。在我们对肺的前瞻性研究中f 在CF中，我们确定了特定的IgG m3，以测试其作为急性肝癌生物标志物的适用性 f 疾病并作为后续参数。

在这项前瞻性单中心研究中，从2016年至2019年对109例CF患者进行了筛查。 f-相关疾病。根据诊断标准，将其分为四组（对照组，支气管炎，ABPA，肺炎）。比较各组的水平f特异性IgG（ImmunoCAP Gm3）。我们进行了接收器工作特性（ROC）曲线分析，以确定临界值，敏感性和特异性。可以招募21名患者进行随访检查。

在109例患者中，有36例被归为急性 f-疾病 （f 支气管炎，ABPA， f肺炎）。其中，有21名患者完成了随访筛查。中位数f特异性Gm3在急性期较高 f-疾病组。在f特异性IgG m3与无急性对照组相比 f-疾病。总体而言，Gm3在个人之间分布较大。计算得出的Gm3截断值为78.05 mg / L，可区分对照组和ABPA /肺炎患者，其特异性为75％，敏感性为74.6％。对21例患者进行的随访检查显示，大多数患者中Gm3的降低无统计学意义，原因是随访患者的数量较少。

f 特异性IgG可能是急性ABPA和急性ABPA有用的生物标志物。 f 肺炎，但不是 f CF中的支气管炎。但是，由于Gm3的个体差异较大，因此只能与其他生物标记一起解释。因此，由于其广泛的可用性，它可能适合用作ABPA和f 如果更大的多中心队列研究可以支持CF的肺炎。